Summary by Moomoo AI
On December 16, 2024, HANSOH PHARMA announced that its independently developed new antibody-drug conjugate (ADC) injection HS-20110 has received the drug clinical trial approval notice from the National Medical Products Administration (NMPA) of China. The drug is intended for clinical trials in advanced solid tumors, marking an important advancement for the company in the field of cancer treatment.The approval of the clinical trial for HS-20110 is the latest achievement of HANSOH PHARMA in the ADC field, reflecting the company's ongoing investment in the development of Innovative Drugs. As a new antibody-drug conjugate, HS-20110 is expected to provide new treatment options for patients with advanced solid tumors. This clinical trial approval will enable HANSOH PHARMA to further assess the safety and efficacy of HS-20110, laying the foundation for the potential market launch of the drug in the future.